Available to mentor
Toshi received his B.S. from Osaka University, Japan, and his Ph.D. in Life Sciences from the University of Tokyo for studies on the metabolic regulation of macrophages with Dr. Motoharu Seiki at the Institute of Medical Science, the University of Tokyo. He was trained as a molecular biologist. He then joined the laboratory of Dr. Inder Verma, later of Dr. Tony Hunter, at the Salk Institute for Biological Studies, La Jolla. He initiated his postdoctoral work on intratumoral heterogeneity in glioblastoma by combining a mouse model of glioma with lineage tracing approaches, including lentiviral barcoding for single-cell RNA-seq in collaboration with Dr. Aviv Regev at the Broad Institute of MIT and Harvard. In 2019, he then, as a research fellow, joined Dr. Mario Suva’s laboratory in the Department of Pathology at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), and the Broad Institute. His postdoctoral studies delineated cellular states and plasticity in human glioblastoma and uncovered their molecular and cellular determinants. Working with clinical fellows and computational scientists, Toshi identified the joy of collaboration and the power of diverse perspectives in a team.
-
Research FellowHarvard Medical School, Broad Institute of Harvard & MIT, 2023
-
Research AssociateSalk Institute for Biological Studies, La Jolla, 2019
-
Postdoctoral FellowUniversity of Tokyo, Tokyo, 2013
-
Ph.D.University of Tokyo, 2013
-
M.S.University of Tokyo Hospital, 2010
-
B.S.Osaka University, 2008
-
Center MemberBiointerfaces Institute
-
Center MemberRogel Cancer Center
-
Center MemberCenter for Computational Medicine and Bioinformatics
Measuring molecular and cellular heterogeneity in human cancers using genomics platforms. Integrating genetic and genomics tools into cell and animal model systems to study human cancers. Dissecting and engineering cell-to-cell interactions of brain tumor ecosystems
-
Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, Eichhorn SW, Greenwald AC, Kinker GS, Rodman C, Gonzalez Castro LN, Wakimoto H, Rozenblatt-Rosen O, Zhuang X, Fan J, Hunter T, Verma IM, Wucherpfennig KW, Regev A, Suvà ML, Tirosh I. Cancer Cell, 2025 Jun 9; 43 (6): 1175 - 1176.Journal ArticleInteractions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.
DOI:10.1016/j.ccell.2025.05.007 PMID: 40436018 -
Takahashi M, Mukhamejanova D, Jasewicz H, Acharya N, Moon JJ, Hara T. Cancer Sci, 2025 Jun; 116 (6): 1482 - 1499.Journal ArticleOpportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy.
DOI:10.1111/cas.70052 PMID: PMC12127102 -
Mangena V, Chanoch-Myers R, Sartore R, Paulsen B, Gritsch S, Weisman H, Hara T, Breakefield XO, Breyne K, Regev A, Chung K, Arlotta P, Tirosh I, Suvà ML. Cancer Discov, 2025 Feb 7; 15 (2): 299 - 315.Journal ArticleGlioblastoma Cortical Organoids Recapitulate Cell-State Heterogeneity and Intercellular Transfer.
DOI:10.1158/2159-8290.CD-23-1336 PMID: PMC11803396 -
Kardani K, Ghouse SM, Din Abdul Jabbar MA, Rajasubramanian N, Sanchez Gil J, Stemmer-Rachamimov A, Soda Y, Martuza RL, Hara T, Wakimoto H, Rabkin SD. Neurooncol Adv, 2025 7 (1): vdae215Journal ArticleImmunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes.
DOI:10.1093/noajnl/vdae215 PMID: PMC11783566 -
Schiffman JS, D'Avino AR, Prieto T, Pang Y, Fan Y, Rajagopalan S, Potenski C, Hara T, Suvà ML, Gawad C, Landau DA. Nat Genet, 2024 Oct; 56 (10): 2174 - 2184.Journal ArticleDefining heritability, plasticity, and transition dynamics of cellular phenotypes in somatic evolution.
DOI:10.1038/s41588-024-01920-6 PMID: PMC11527590 -
Takahashi M, Chong HB, Zhang S, Yang T-Y, Lazarov MJ, Harry S, Maynard M, Hilbert B, White RD, Murrey HE, Tsou C-C, Vordermark K, Assaad J, Gohar M, Dürr BR, Richter M, Patel H, Kryukov G, Brooijmans N, Alghali ASO, Rubio K, Villanueva A, Zhang J, Ge M, Makram F, Griesshaber H, Harrison D, Koglin A-S, Ojeda S, Karakyriakou B, Healy A, Popoola G, Rachmin I, Khandelwal N, Neil JR, Tien P-C, Chen N, Hosp T, van den Ouweland S, Hara T, Bussema L, Dong R, Shi L, Rasmussen MQ, Domingues AC, Lawless A, Fang J, Yoda S, Nguyen LP, Reeves SM, Wakefield FN, Acker A, Clark SE, Dubash T, Kastanos J, Oh E, Fisher DE, Maheswaran S, Haber DA, Boland GM, Sade-Feldman M, Jenkins RW, Hata AN, Bardeesy NM, Suvà ML, Martin BR, Liau BB, Ott CJ, Rivera MN, Lawrence MS, Bar-Peled L. Cell, 2024 May 9; 187 (10): 2536 - 2556.e30.Journal ArticleDrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
DOI:10.1016/j.cell.2024.03.027 PMID: PMC11143475 -
Kardani K, Ghouse SM, Hara T, Soda Y, Stemmer-Rachamimov A, Wakimoto H, Rabkin S. Neuro-Oncology, 2023 Nov 12; 25 (Supplement_5): v309 - v310.Journal ArticleMODL-49. NEW MURINE GLIOBLASTOMA STEM-LIKE CELL MODELS
DOI:10.1093/neuonc/noad179.1200 PMID: PMC10640120 -
Hara T, Chanoch-Myers R, Bussema L, Greenwald A, Behnan J, Wakimoto H, Galli R, Tirosh I, Suva M. Neuro-Oncology, 2023 Nov 12; 25 (Supplement_5): v169 - v169.Journal ArticlePATH-11. POOLED IN VIVO ASSAY TO CHARACTERIZE GLIOBLASTOMA INVASION AT THE SINGLE-CELL RESOLUTION
DOI:10.1093/neuonc/noad179.0641 PMID: PMC10639758
